Atlas Trials

Identification of Early Markers of Response and Resistance to Trastuzumab

Clinical trial NCT01834950 · COMPLETED

Trial details

NCT number
NCT01834950
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
Start date
2013-03-27
Primary completion
2017-12-10
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.